ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Saturday, 21 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call Transcript

Shree Ganesh Remedies Earnings Call Transcript: Key Takeaways

Q2 revenue ₹23.29 Cr, up 62% QoQ but down 23% YoY; EBITDA margin fell to 17% from 32%. Management's 'stronger performance ahead' has no numbers, and it admits the recovery is incomplete.

Shree Ganesh Remedies Q2 FY27 concall: date, live audio and summaryConcall page →
Highlights
Revenue growthRevenue ₹23.29 Cr: +62% QoQ, -23% YoY; recovering from weak Q1.
MarginsEBITDA margin 17% vs 23% Q1 and 32% Q2 FY26; contracting.
Demand visibilityEuropean demand subdued; domestic pivot; RFQs rising; no volume outlook.
Management confidenceBalanced; admits recovery incomplete; optimism largely qualitative.

Growth

Revenue +62% QoQ off weak Q1, but -23% YoY. EBITDA -59% YoY; PAT -67% YoY.

Outlook

No revenue or margin guidance given. Commercial supply from Q1 FY28; ~80% plant utilisation at peak, in three years.

Risks

Opex +76% vs revenue +62%; European order deferrals; inventory build-up; no firm commercial supply date beyond Q1 FY28.

Source

Earnings Call Transcript filed with BSE, NSE: SGRL. Summary written with AI assistance from the document.

Read the document ↗

Shree Ganesh Remedies Ltd: key numbers

Share price
₹605.80
Market cap
₹777.7 Cr
Revenue (annual)
₹109.3 Cr
Net profit (annual)
₹17.76 Cr
P/E (TTM)
64.2×Sector 49.0×
Promoter holding
72.84%+0.00% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Shree Ganesh Remedies Ltd

All →